John Bogdanos

Molecular mechanisms and clinical management of cancer bone metastasis

ERBB receptors and cancer: the complexity of targeted inhibitors

Insulin-Like Growth Factor (IGF) family and prostate cancer

Cushing's syndrome

Macrophages in immunoregulation and therapeutics

Epidemiology of Prostate Cancer

Ursolic acid: An anti‐ and pro‐inflammatory triterpenoid

The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer

Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells

Pasireotide (SOM230): Development, mechanism of action and potential applications

Cancer prevention by tea: animal studies, molecular mechanisms and human relevance

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them

Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy.

Satellite Cells and the Muscle Stem Cell Niche

Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer